Multiplex Assay Kit for Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay)

APCS; PTX2; Pentaxin-Related; 9.5S Alpha-1-Glycoprotein

(Note: Up to 8-plex in one testing reaction)

Specificity

This assay has high sensitivity and excellent specificity for detection of Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay).
No significant cross-reactivity or interference between Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) and analogues was observed.

Recovery

Matrices listed below were spiked with certain level of recombinant Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) and the recovery rates were calculated by comparing the measured value to the expected amount of Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) in samples.

Matrix Recovery range (%) Average(%)
serum(n=5) 81-92 85
EDTA plasma(n=5) 78-97 86
heparin plasma(n=5) 89-98 93
sodium citrate plasma(n=5) 98-105 102

Precision

Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%

Linearity

The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.

Sample 1:2 1:4 1:8 1:16
serum(n=5) 79-101% 98-105% 93-102% 86-96%
EDTA plasma(n=5) 82-96% 87-94% 92-101% 82-89%
heparin plasma(n=5) 82-95% 96-105% 86-101% 96-105%
sodium citrate plasma(n=5) 95-102% 89-103% 90-104% 84-103%

Stability

The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.

Reagents and materials provided

Reagents Quantity Reagents Quantity
96-well plate 1 Plate sealer for 96 wells 4
Pre-Mixed Standard 2 Standard Diluent 1×20mL
Pre-Mixed Magnetic beads (22#:SAP) 1 Analysis buffer 1×20mL
Pre-Mixed Detection Reagent A 1×120μL Assay Diluent A 1×12mL
Detection Reagent B (PE-SA) 1×120μL Assay Diluent B 1×12mL
Sheath Fluid 1×10mL Wash Buffer (30 × concentrate) 1×20mL
Instruction manual 1

Assay procedure summary

1. Preparation of standards, reagents and samples before the experiment;
2. Add 100μL standard or sample to each well,
    add 10μL magnetic beads, and incubate 90min at 37°C on shaker;
3. Remove liquid on magnetic frame, add 100μL prepared Detection Reagent A. Incubate 60min at 37°C on shaker;
4. Wash plate on magnetic frame for three times;
5. Add 100μL prepared Detection Reagent B, and incubate 30 min at 37°C on shaker;
6. Wash plate on magnetic frame for three times;
7. Add 100μL sheath solution, swirl for 2 minutes, read on the machine.

GIVEAWAYS

INCREMENT SERVICES

Magazine Citations
Journal of Vascular Surgery Circulation levels of acute phase proteins in patients with Takayasu arteritis PubMed: 20100644
Journal of Proteome Research Combined Proteomic and Metabolomic Profiling of Serum Reveals Association of the Complement System with Obesity and Identifies Novel Markers of Body Fat Mass Changes ACS: pr2005555
Liver International Identification of candidate biomarkers for hepatocellular carcinoma in plasma of HCV-infected cirrhotic patients by 3-D DIGE Pubmed: 23944848
Journal of Proteome Research Targeted proteomics predict a sustained complete-response after transarterial chemoembolization and clinical outcomes in patients with hepatocellular carcinoma: a prospective cohort study pubmed:28112944
American Journal of Reproductive Immunology Amniotic fluid pentraxins: Potential early markers for identifying intra‐amniotic inflammatory complications in preterm pre‐labor rupture of membranes pubmed:29193454
Theranostics Serum amyloid P component therapeutically attenuates atherosclerosis in mice via its effects on macrophages Pubmed:29930724
J Med Primatol Proteopathic lesions in the brain of a super©\aged chimpanzee (Pan troglodytes) 34096618
Clinical and Experimental Immunology Clinical significance of differential serum-signatures for early prediction of severe dengue among Eastern Indian patients Pubmed:35348620
Catalog No. Related products for research use of Mus musculus (Mouse) Organism species Applications (RESEARCH USE ONLY!)
RPB539Mu01 Recombinant Serum Amyloid P Component (SAP) Positive Control; Immunogen; SDS-PAGE; WB.
RPB539Mu02 Recombinant Serum Amyloid P Component (SAP) Positive Control; Immunogen; SDS-PAGE; WB.
PAB539Mu01 Polyclonal Antibody to Serum Amyloid P Component (SAP) WB; IHC; ICC; IP.
PAB539Mu02 Polyclonal Antibody to Serum Amyloid P Component (SAP) WB; IHC; ICC; IP.
SEB539Mu ELISA Kit for Serum Amyloid P Component (SAP) Enzyme-linked immunosorbent assay for Antigen Detection.
LMB539Mu Multiplex Assay Kit for Serum Amyloid P Component (SAP) ,etc. by FLIA (Flow Luminescence Immunoassay) FLIA Kit for Antigen Detection.